Loading…
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS
Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemother...
Saved in:
| Published in: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2024-12 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c993-8a6d41e88dee12cb5dbedaa379464480a1f7bd0e5482769f0ad9a4672362cc893 |
| container_end_page | |
| container_issue | |
| container_start_page | |
| container_title | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |
| container_volume | |
| creator | Komori, Azusa Hironaka, Shuichi Kadowaki, Shigenori Mitani, Seiichiro Furuta, Mitsuhiro Kawakami, Takeshi Makiyama, Akitaka Takegawa, Naoki Sugiyama, Keiji Hirano, Hidekazu Ando, Takayuki Matsushima, Tomohiro Chida, Akihiko Kashiwada, Tomomi Komoda, Masato Matsumoto, Toshihiko Oda, Hisanobu Yabusaki, Hiroshi Kawakami, Hisato Yamazaki, Kentaro Boku, Narikazu Hyodo, Ichinosuke Yoshimura, Kenichi Muro, Kei |
| description | Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease. MSI status was tested using multiplex PCR fragment analysis (MSI Testing Kit, FALCO). The primary endpoint was the prevalence of MSI-high GC.
Between October 2020 and October 2022, 930 eligible patients from 75 centers in Japan were analyzed. The prevalence of MSI-high GC was 5.6% (95% CI 4.2-7.3). MSI-high GC was more frequently observed in females than males (9.6% vs 3.8%, p |
| doi_str_mv | 10.1007/s10120-024-01579-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3150521897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3150521897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c993-8a6d41e88dee12cb5dbedaa379464480a1f7bd0e5482769f0ad9a4672362cc893</originalsourceid><addsrcrecordid>eNo9kctKJDEUhoMo6rS-gAvJ0k2NudQt7kS0HREUFFyGU6lT3ZGqSpukBvptfFTTtu3q_Pyc-0fIGWd_OWPVZeCMC5YxkWeMF5XKxB455rksMylZsb_TQvEj8ieEd5ayFC8PyZFUlawrJY_J57PH_9DjaJDC2FLT29Eat4K4dL1bWAM97RDi5DFQ19HBGu8CROx7G5HaMURobNLrbGkXSzpghGRFa6jz1KOZvMcx0kVyfTI3MzC41RIWbue9T6OJ1o3UQFrDX9G3h6c5l1Kw-fPLCTnooA94-hNn5PXu9vXmPnt8mv-7uX7MjFIyq6Fsc4513SJyYZqibbAFkJXKyzyvGfCualqGRV6LqlQdg1ZBXlZClsKYWskZudi2XXn3MWGIerDBpCthRDcFLXnBCsHr9LgZEdvUzSeCx06vvB3ArzVnegNGb8HoBEZ_g9EiFZ3_9J-aAdvfkh0J-QU-p4y0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3150521897</pqid></control><display><type>article</type><title>Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS</title><source>Springer Nature</source><creator>Komori, Azusa ; Hironaka, Shuichi ; Kadowaki, Shigenori ; Mitani, Seiichiro ; Furuta, Mitsuhiro ; Kawakami, Takeshi ; Makiyama, Akitaka ; Takegawa, Naoki ; Sugiyama, Keiji ; Hirano, Hidekazu ; Ando, Takayuki ; Matsushima, Tomohiro ; Chida, Akihiko ; Kashiwada, Tomomi ; Komoda, Masato ; Matsumoto, Toshihiko ; Oda, Hisanobu ; Yabusaki, Hiroshi ; Kawakami, Hisato ; Yamazaki, Kentaro ; Boku, Narikazu ; Hyodo, Ichinosuke ; Yoshimura, Kenichi ; Muro, Kei</creator><creatorcontrib>Komori, Azusa ; Hironaka, Shuichi ; Kadowaki, Shigenori ; Mitani, Seiichiro ; Furuta, Mitsuhiro ; Kawakami, Takeshi ; Makiyama, Akitaka ; Takegawa, Naoki ; Sugiyama, Keiji ; Hirano, Hidekazu ; Ando, Takayuki ; Matsushima, Tomohiro ; Chida, Akihiko ; Kashiwada, Tomomi ; Komoda, Masato ; Matsumoto, Toshihiko ; Oda, Hisanobu ; Yabusaki, Hiroshi ; Kawakami, Hisato ; Yamazaki, Kentaro ; Boku, Narikazu ; Hyodo, Ichinosuke ; Yoshimura, Kenichi ; Muro, Kei ; West Japan Oncology Group (WJOG)</creatorcontrib><description>Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease. MSI status was tested using multiplex PCR fragment analysis (MSI Testing Kit, FALCO). The primary endpoint was the prevalence of MSI-high GC.
Between October 2020 and October 2022, 930 eligible patients from 75 centers in Japan were analyzed. The prevalence of MSI-high GC was 5.6% (95% CI 4.2-7.3). MSI-high GC was more frequently observed in females than males (9.6% vs 3.8%, p < 0.001), patients aged ≥ 70 years compared to those < 70 years (8.0% vs 2.8%, p < 0.001), in the lower stomach than other locations (10.5% vs 3.2%, p < 0.001), HER2-negative tumors than HER2-positive tumors (6.5% vs 1.8%, p = 0.02), and in patients without liver metastasis than those with liver metastasis (6.9% vs 2.2%, p = 0.004).
The prevalence of MSI-high tumors among chemotherapy-naïve patients with unresectable GC was 5.6%. These tumors were associated with female sex, older age, lower stomach, HER2-negative, and absence of liver metastasis. These findings would help assuming MSI-high tumors and may have significant implications for clinical practice and studies targeting this GC subtype.</description><identifier>ISSN: 1436-3291</identifier><identifier>ISSN: 1436-3305</identifier><identifier>EISSN: 1436-3305</identifier><identifier>DOI: 10.1007/s10120-024-01579-2</identifier><identifier>PMID: 39738793</identifier><language>eng</language><publisher>Japan</publisher><ispartof>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-12</ispartof><rights>2024. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c993-8a6d41e88dee12cb5dbedaa379464480a1f7bd0e5482769f0ad9a4672362cc893</cites><orcidid>0000-0001-9714-231X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39738793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Komori, Azusa</creatorcontrib><creatorcontrib>Hironaka, Shuichi</creatorcontrib><creatorcontrib>Kadowaki, Shigenori</creatorcontrib><creatorcontrib>Mitani, Seiichiro</creatorcontrib><creatorcontrib>Furuta, Mitsuhiro</creatorcontrib><creatorcontrib>Kawakami, Takeshi</creatorcontrib><creatorcontrib>Makiyama, Akitaka</creatorcontrib><creatorcontrib>Takegawa, Naoki</creatorcontrib><creatorcontrib>Sugiyama, Keiji</creatorcontrib><creatorcontrib>Hirano, Hidekazu</creatorcontrib><creatorcontrib>Ando, Takayuki</creatorcontrib><creatorcontrib>Matsushima, Tomohiro</creatorcontrib><creatorcontrib>Chida, Akihiko</creatorcontrib><creatorcontrib>Kashiwada, Tomomi</creatorcontrib><creatorcontrib>Komoda, Masato</creatorcontrib><creatorcontrib>Matsumoto, Toshihiko</creatorcontrib><creatorcontrib>Oda, Hisanobu</creatorcontrib><creatorcontrib>Yabusaki, Hiroshi</creatorcontrib><creatorcontrib>Kawakami, Hisato</creatorcontrib><creatorcontrib>Yamazaki, Kentaro</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Hyodo, Ichinosuke</creatorcontrib><creatorcontrib>Yoshimura, Kenichi</creatorcontrib><creatorcontrib>Muro, Kei</creatorcontrib><creatorcontrib>West Japan Oncology Group (WJOG)</creatorcontrib><title>Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS</title><title>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</title><addtitle>Gastric Cancer</addtitle><description>Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease. MSI status was tested using multiplex PCR fragment analysis (MSI Testing Kit, FALCO). The primary endpoint was the prevalence of MSI-high GC.
Between October 2020 and October 2022, 930 eligible patients from 75 centers in Japan were analyzed. The prevalence of MSI-high GC was 5.6% (95% CI 4.2-7.3). MSI-high GC was more frequently observed in females than males (9.6% vs 3.8%, p < 0.001), patients aged ≥ 70 years compared to those < 70 years (8.0% vs 2.8%, p < 0.001), in the lower stomach than other locations (10.5% vs 3.2%, p < 0.001), HER2-negative tumors than HER2-positive tumors (6.5% vs 1.8%, p = 0.02), and in patients without liver metastasis than those with liver metastasis (6.9% vs 2.2%, p = 0.004).
The prevalence of MSI-high tumors among chemotherapy-naïve patients with unresectable GC was 5.6%. These tumors were associated with female sex, older age, lower stomach, HER2-negative, and absence of liver metastasis. These findings would help assuming MSI-high tumors and may have significant implications for clinical practice and studies targeting this GC subtype.</description><issn>1436-3291</issn><issn>1436-3305</issn><issn>1436-3305</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kctKJDEUhoMo6rS-gAvJ0k2NudQt7kS0HREUFFyGU6lT3ZGqSpukBvptfFTTtu3q_Pyc-0fIGWd_OWPVZeCMC5YxkWeMF5XKxB455rksMylZsb_TQvEj8ieEd5ayFC8PyZFUlawrJY_J57PH_9DjaJDC2FLT29Eat4K4dL1bWAM97RDi5DFQ19HBGu8CROx7G5HaMURobNLrbGkXSzpghGRFa6jz1KOZvMcx0kVyfTI3MzC41RIWbue9T6OJ1o3UQFrDX9G3h6c5l1Kw-fPLCTnooA94-hNn5PXu9vXmPnt8mv-7uX7MjFIyq6Fsc4513SJyYZqibbAFkJXKyzyvGfCualqGRV6LqlQdg1ZBXlZClsKYWskZudi2XXn3MWGIerDBpCthRDcFLXnBCsHr9LgZEdvUzSeCx06vvB3ArzVnegNGb8HoBEZ_g9EiFZ3_9J-aAdvfkh0J-QU-p4y0</recordid><startdate>20241231</startdate><enddate>20241231</enddate><creator>Komori, Azusa</creator><creator>Hironaka, Shuichi</creator><creator>Kadowaki, Shigenori</creator><creator>Mitani, Seiichiro</creator><creator>Furuta, Mitsuhiro</creator><creator>Kawakami, Takeshi</creator><creator>Makiyama, Akitaka</creator><creator>Takegawa, Naoki</creator><creator>Sugiyama, Keiji</creator><creator>Hirano, Hidekazu</creator><creator>Ando, Takayuki</creator><creator>Matsushima, Tomohiro</creator><creator>Chida, Akihiko</creator><creator>Kashiwada, Tomomi</creator><creator>Komoda, Masato</creator><creator>Matsumoto, Toshihiko</creator><creator>Oda, Hisanobu</creator><creator>Yabusaki, Hiroshi</creator><creator>Kawakami, Hisato</creator><creator>Yamazaki, Kentaro</creator><creator>Boku, Narikazu</creator><creator>Hyodo, Ichinosuke</creator><creator>Yoshimura, Kenichi</creator><creator>Muro, Kei</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9714-231X</orcidid></search><sort><creationdate>20241231</creationdate><title>Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS</title><author>Komori, Azusa ; Hironaka, Shuichi ; Kadowaki, Shigenori ; Mitani, Seiichiro ; Furuta, Mitsuhiro ; Kawakami, Takeshi ; Makiyama, Akitaka ; Takegawa, Naoki ; Sugiyama, Keiji ; Hirano, Hidekazu ; Ando, Takayuki ; Matsushima, Tomohiro ; Chida, Akihiko ; Kashiwada, Tomomi ; Komoda, Masato ; Matsumoto, Toshihiko ; Oda, Hisanobu ; Yabusaki, Hiroshi ; Kawakami, Hisato ; Yamazaki, Kentaro ; Boku, Narikazu ; Hyodo, Ichinosuke ; Yoshimura, Kenichi ; Muro, Kei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c993-8a6d41e88dee12cb5dbedaa379464480a1f7bd0e5482769f0ad9a4672362cc893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Komori, Azusa</creatorcontrib><creatorcontrib>Hironaka, Shuichi</creatorcontrib><creatorcontrib>Kadowaki, Shigenori</creatorcontrib><creatorcontrib>Mitani, Seiichiro</creatorcontrib><creatorcontrib>Furuta, Mitsuhiro</creatorcontrib><creatorcontrib>Kawakami, Takeshi</creatorcontrib><creatorcontrib>Makiyama, Akitaka</creatorcontrib><creatorcontrib>Takegawa, Naoki</creatorcontrib><creatorcontrib>Sugiyama, Keiji</creatorcontrib><creatorcontrib>Hirano, Hidekazu</creatorcontrib><creatorcontrib>Ando, Takayuki</creatorcontrib><creatorcontrib>Matsushima, Tomohiro</creatorcontrib><creatorcontrib>Chida, Akihiko</creatorcontrib><creatorcontrib>Kashiwada, Tomomi</creatorcontrib><creatorcontrib>Komoda, Masato</creatorcontrib><creatorcontrib>Matsumoto, Toshihiko</creatorcontrib><creatorcontrib>Oda, Hisanobu</creatorcontrib><creatorcontrib>Yabusaki, Hiroshi</creatorcontrib><creatorcontrib>Kawakami, Hisato</creatorcontrib><creatorcontrib>Yamazaki, Kentaro</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Hyodo, Ichinosuke</creatorcontrib><creatorcontrib>Yoshimura, Kenichi</creatorcontrib><creatorcontrib>Muro, Kei</creatorcontrib><creatorcontrib>West Japan Oncology Group (WJOG)</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Komori, Azusa</au><au>Hironaka, Shuichi</au><au>Kadowaki, Shigenori</au><au>Mitani, Seiichiro</au><au>Furuta, Mitsuhiro</au><au>Kawakami, Takeshi</au><au>Makiyama, Akitaka</au><au>Takegawa, Naoki</au><au>Sugiyama, Keiji</au><au>Hirano, Hidekazu</au><au>Ando, Takayuki</au><au>Matsushima, Tomohiro</au><au>Chida, Akihiko</au><au>Kashiwada, Tomomi</au><au>Komoda, Masato</au><au>Matsumoto, Toshihiko</au><au>Oda, Hisanobu</au><au>Yabusaki, Hiroshi</au><au>Kawakami, Hisato</au><au>Yamazaki, Kentaro</au><au>Boku, Narikazu</au><au>Hyodo, Ichinosuke</au><au>Yoshimura, Kenichi</au><au>Muro, Kei</au><aucorp>West Japan Oncology Group (WJOG)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS</atitle><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle><addtitle>Gastric Cancer</addtitle><date>2024-12-31</date><risdate>2024</risdate><issn>1436-3291</issn><issn>1436-3305</issn><eissn>1436-3305</eissn><abstract>Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease. MSI status was tested using multiplex PCR fragment analysis (MSI Testing Kit, FALCO). The primary endpoint was the prevalence of MSI-high GC.
Between October 2020 and October 2022, 930 eligible patients from 75 centers in Japan were analyzed. The prevalence of MSI-high GC was 5.6% (95% CI 4.2-7.3). MSI-high GC was more frequently observed in females than males (9.6% vs 3.8%, p < 0.001), patients aged ≥ 70 years compared to those < 70 years (8.0% vs 2.8%, p < 0.001), in the lower stomach than other locations (10.5% vs 3.2%, p < 0.001), HER2-negative tumors than HER2-positive tumors (6.5% vs 1.8%, p = 0.02), and in patients without liver metastasis than those with liver metastasis (6.9% vs 2.2%, p = 0.004).
The prevalence of MSI-high tumors among chemotherapy-naïve patients with unresectable GC was 5.6%. These tumors were associated with female sex, older age, lower stomach, HER2-negative, and absence of liver metastasis. These findings would help assuming MSI-high tumors and may have significant implications for clinical practice and studies targeting this GC subtype.</abstract><cop>Japan</cop><pmid>39738793</pmid><doi>10.1007/s10120-024-01579-2</doi><orcidid>https://orcid.org/0000-0001-9714-231X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1436-3291 |
| ispartof | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-12 |
| issn | 1436-3291 1436-3305 1436-3305 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3150521897 |
| source | Springer Nature |
| title | Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T10%3A25%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20clinicopathological%20features%20of%20microsatellite%20instability-high%20metastatic%20or%20recurrent%20gastric%20and%20esophagogastric%20junction%20cancer:%20WJOG13320GPS&rft.jtitle=Gastric%20cancer%20:%20official%20journal%20of%20the%20International%20Gastric%20Cancer%20Association%20and%20the%20Japanese%20Gastric%20Cancer%20Association&rft.au=Komori,%20Azusa&rft.aucorp=West%20Japan%20Oncology%20Group%20(WJOG)&rft.date=2024-12-31&rft.issn=1436-3291&rft.eissn=1436-3305&rft_id=info:doi/10.1007/s10120-024-01579-2&rft_dat=%3Cproquest_cross%3E3150521897%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c993-8a6d41e88dee12cb5dbedaa379464480a1f7bd0e5482769f0ad9a4672362cc893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3150521897&rft_id=info:pmid/39738793&rfr_iscdi=true |